Loading…
Pulmatrix, Inc. is projected to rise to $1.90 by 2027, a +9% move from its current price of $1.74. PULM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.69 | $1.74 | $1.79 | -0.03% |
| Aug 6 | $1.67 | $1.74 | $1.81 | -0.05% |
| Aug 7 | $1.65 | $1.74 | $1.83 | -0.08% |
| Aug 8 | $1.64 | $1.74 | $1.84 | -0.11% |
| Aug 9 | $1.63 | $1.74 | $1.86 | -0.14% |
| Aug 10 | $1.62 | $1.74 | $1.87 | -0.16% |
| Aug 11 | $1.61 | $1.74 | $1.88 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.61 | $1.74 | $1.88 | -0.19% |
| Week 2 | $1.55 | $1.73 | $1.94 | -0.38% |
| Week 3 | $1.51 | $1.73 | $1.98 | -0.57% |
| Week 4 | $1.48 | $1.73 | $2.02 | -0.76% |
| Week 5 | $1.45 | $1.72 | $2.05 | -0.95% |
| Week 6 | $1.42 | $1.72 | $2.08 | -1.14% |
| Week 7 | $1.40 | $1.72 | $2.11 | -1.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pulmatrix, Inc. is a biopharmaceutical company focused on developing novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. It offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.
The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Pulmatrix, Inc. (PULM) trades at $1.69 per share with a market cap of $6.17M, ranking 5076. The stock sits in the Healthcare category.
A major floor 31.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 8.0% above — a clean break opens room to run.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key PULM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PULM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.70 | Buy | $1.71 | Buy |
| MA 10 | $1.70 | Buy | $1.70 | Buy |
| MA 20 | $1.70 | Buy | $1.68 | Buy |
| MA 50 | $1.55 | Buy | $1.62 | Buy |
| MA 100 | $1.53 | Buy | $1.79 | Sell |
| MA 200 | $2.50 | Sell | $2.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.80 | Neutral |
| Stoch RSI (14) | 65.05 | Neutral |
| CCI (20) | 52.60 | Neutral |
| Williams %R (14) | -15.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 10.83 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 85.00 | Sell |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 55.98 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 1.70 | Buy |
| ADX (14) | 16.13 | Neutral |
| ATR (14) | 0.05 | Info |
The near-term technical picture is NEUTRAL. The RSI14 is 60, and the stock sits above the 50-day simple moving average (SMA50) of $1.47 but below the 200-day simple moving average (SMA200) of $2.66.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.74 | $2.26 | 0% | Neutral | |
| $1.50 | $1.90 | $2.54 | +9% | Neutral | |
| $1.60 | $2.09 | $2.91 | +20% | Bullish | |
| $1.51 | $2.02 | $2.91 | +16% | Neutral | |
| $1.61 | $2.20 | $3.25 | +27% | Bullish | |
| $2.01 | $2.81 | $4.25 | +62% | Bullish | |
| $2.28 | $3.24 | $5.00 | +86% | Bullish | |
| $2.34 | $3.39 | $5.33 | +95% | Bullish | |
| $2.29 | $3.38 | $5.40 | +94% | Bullish | |
| $2.39 | $3.58 | $5.82 | +106% | Bullish | |
| $3.42 | $5.53 | $9.59 | +218% | Bullish | |
| $5.30 | $9.76 | $18.60 | +461% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.19 | $1.74 | $2.13 | +0.00% |
| September 2026 | $1.46 | $1.73 | $2.11 | -0.52% |
| October 2026 | $1.42 | $1.70 | $2.10 | -1.94% |
| November 2026 | $1.46 | $1.76 | $2.19 | +3.43% |
| December 2026 | $1.49 | $1.80 | $2.26 | +2.37% |
Click any year to see its month-by-month PULM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PULM is projected to trade between $1.19 and $2.26, averaging $1.74 — a potential gain of 0% from today's $1.74. A consolidation phase looks the most probable path here.
Pulmatrix, Inc.'s 2027 outlook centres on $1.90, within a $1.50 to $2.54 range. That is up +9% on the projected 2026 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2028, PULM could reach as high as $2.91, with a base case around $2.09 and support toward $1.60 — roughly +20% from $1.74. Buyers look set to stay in control over this stretch.
Expect PULM to range from $1.51 to $2.91 through 2029. The $2.02 average target implies a +16% move from current prices. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
The PULM price prediction for 2030 points to an average of $2.20 (low $1.61, high $3.25) — a potential gain of +27% on today's $1.74. Buyers look set to stay in control over this stretch.
In 2031, PULM is projected to trade between $2.01 and $4.25, averaging $2.81 — a potential gain of +62% from today's $1.74. That is up +28% on the projected 2030 average. Momentum favours further upside here.
Pulmatrix, Inc.'s 2032 outlook centres on $3.24, within a $2.28 to $5.00 range. That is up +15% on the projected 2031 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PULM could reach as high as $5.33, with a base case around $3.39 and support toward $2.34 — roughly +95% from $1.74. Momentum favours further upside here.
Expect PULM to range from $2.29 to $5.40 through 2034. The $3.38 average target implies a +94% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The PULM price prediction for 2035 points to an average of $3.58 (low $2.39, high $5.82) — a potential gain of +106% on today's $1.74. Momentum favours further upside here.
In 2040, PULM is projected to trade between $3.42 and $9.59, averaging $5.53 — a potential gain of +218% from today's $1.74. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Pulmatrix, Inc.'s 2050 outlook centres on $9.76, within a $5.30 to $18.60 range. That is up +76% on the projected 2040 average. That marks a +461% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PULM today (≈ 574.712644 PULM) could be worth
$5,606.93
+$4,606.93 (+461%) by 2050 · US Dollar
Based on the average projected PULM price of $9.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PULMwould be worth at today's price.
$1,000 invested in PULM on Jul 31, 2025 (≈ 177.61989 PULM) would be worth
$309.06
-$690.94 (-69.1%) today · 0.31× · US Dollar
Based on a PULM entry price of $5.63 vs. today's $1.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.65 | $1,054.55 | +5.5% |
| 1 month ago | $1.74 | $1,000 | -0.0% |
| 3 months ago | $1.29 | $1,348.84 | +34.9% |
| 6 months ago | $2.59 | $671.81 | -32.8% |
| 1 year ago | $5.63 | $309.06 | -69.1% |
| All time (5.0y) ago | $16.56 | $105.07 | -89.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PULM forecast.
Our base-case forecast reaches $3.50 around 2035.
Implied market cap at $3.50: $12.78M
The multi-year forecast shows bullish upside, with 2030 at an average of $2.24 and an ROI of 32.5; 2040 at an average of $5.87 with an ROI of 247.6; and 2050 at an average of $10.50 with an ROI of 521.2. Earlier years illustrate continued growth, such as 2027 avg $1.87 with ROI 10.4 and 2028 avg $2.10 with ROI 24.3. By 2031 the avg is $2.98 (ROI 76.6) and 2035 the avg is $3.63 (ROI 114.7).
These figures imply a rising long-term path, but they are estimates and not guarantees, subject to market and company-specific factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.24 with an ROI of 32.5.
Forecasts indicate a path to higher prices over time, with an average price of $2.24 in 2030 and $10.50 in 2050, and ROIs up to 521.2% by 2050, but these are estimates and not guaranteed.
Yes. The 2030 max is $3.35 and the 2040 max is $10.37; the 2031-2035 period also shows higher highs, with 2035 max at $5.98 and 2033 max at $5.55.
The 2035 forecast shows an average price of $3.63 with a max of $5.98 and an ROI of 114.7.
The 2050 forecast shows an average price of $10.50 with a max of $20.43 and an ROI of 521.2.
Pulmatrix, Inc. Community Discussion
0Share your Pulmatrix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.